Progentec Diagnostics
Progentec Diagnostics, Inc. is a company focused on the proactive care of autoimmune diseases like lupus and multiple sclerosis (MS) through a combination of proteomics and digital health. Their core offerings include the aiSLE® DX Flare Risk Index and aiSLE® DX Disease Activity Index (LiquidSLEDAI™) tests, which aim to predict disease flares and monitor activity, offering a significant advancement over existing scales. The company is also developing digital biomarkers through initiatives like the OASIS study, utilizing remote monitoring and patient-reported outcomes via the LupusCorner Research app. Progentec's vision is to improve health outcomes by providing data-driven, proactive healthcare solutions that limit organ damage, reduce flare severity, and personalize patient care. Their business model appears to be a combination of diagnostic test sales, R&D services, and digital health platform offerings. The company has a strong team of experienced professionals in medicine, research, and technology, including a significant patient community of over 120,000 Lupus Warriors engaged with their LupusCorner platform.
Progentec Diagnostics
Progentec Diagnostics, Inc. is a company focused on the proactive care of autoimmune diseases like lupus and multiple sclerosis (MS) through a combination of proteomics and digital health. Their core offerings include the aiSLE® DX Flare Risk Index and aiSLE® DX Disease Activity Index (LiquidSLEDAI™) tests, which aim to predict disease flares and monitor activity, offering a significant advancement over existing scales. The company is also developing digital biomarkers through initiatives like the OASIS study, utilizing remote monitoring and patient-reported outcomes via the LupusCorner Research app. Progentec's vision is to improve health outcomes by providing data-driven, proactive healthcare solutions that limit organ damage, reduce flare severity, and personalize patient care. Their business model appears to be a combination of diagnostic test sales, R&D services, and digital health platform offerings. The company has a strong team of experienced professionals in medicine, research, and technology, including a significant patient community of over 120,000 Lupus Warriors engaged with their LupusCorner platform.
TL;DR
Focus: Proteomics and digital-health solutions for autoimmune diseases (notably lupus and MS)
Flagship tests: aiSLE DX Flare Risk Index and aiSLE DX Disease Activity Index (LiquidSLEDAI)
Lab status: Operates a CLIA-certified, CAP-accredited high-complexity clinical laboratory
Location & scale: Headquartered/lab in Oklahoma City; ~16 employees reported
$6.25M reported (other profiles report up to $8.75M including a $5M Series A)